NurExone (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone“) is a pioneering biopharmaceutical company developing regenerative medicine therapies.
For a quick catch up on NRX, here are some of the most salient facts about this innovative Company.
Research Report (Target price $4.00)
Company Presentations/Information sheets
The latest key development is that the Company welcomed Dr. Ram Petter, Ph.D., MBA, as a consultant to assist in driving the Company’s strategic collaborations. This new ‘acquisition’ showcases NRX’s desire to increase its partnerships and licensing.
Dr. Petter’s bona fides include:
- Senior Biotechnological / Biopharmaceutical professional with 25 years in leadership positions with increasing responsibility. Significant experience in Bio Operations, Manufacturing, R&D, Strategic Planning, Portfolio Development, Business Development, General Management (P&L responsibility), Commercial negotiations and alliance management across multiple cultures and geographies.
- Creative & and focused thinking, daring and driven by challenges
- Enthusiastic with the development of organizations, teams and talented individuals
- Played leading roles in developing, submitting, approving, launching, and commercial manufacturing of Novel and Biosimilar products. (Linkedin)
“Our ExoTherapy platform for drug delivery is ready for industry partnerships targeting clinical indications beyond acute spinal cord injury,” says Dr. Lior Shaltiel, CEO of NurExone. “Ram’s extensive experience and strategic acumen will be most helpful in forging these critical collaborations.” Adding someone with such experience in pharmaceuticals and the business side is likely a game changer for NRX.
I also found a great article that digs into the company to give confidence to buy some potentially. A few highlights of the NATURE piece;
- At the forefront of developing exosomes into next-generation nanocarriers for drug delivery.
- Exosomes play an essential biological role in intercellular communication and transmission of macromolecules between cells.
- Vehicles for the delivery of active pharmaceutical ingredients (APIs), from small molecules and peptides to proteins and nucleic acids, as an alternative to other kinds of nanocarriers such as lipid vesicles and cell-based gene therapies.
- They do not elicit the immune solid responses that often hamper allogeneic cell-based therapies, which are used to deliver therapeutic molecules and genes to patients.
- NurExone’s ambitious goal is to market a novel treatment for acute spinal cord injuries (SCIs) derived from the ExoTherapy platform, ExoPTEN.
- NurExone’s ambitious goal is to market a novel treatment for acute spinal cord injuries (SCIs) derived from the ExoTherapy platform, ExoPTEN.
NRX seems to be making all the right moves product-wise and maintaining a robust program of partnerships and licensing. The company’s Orphan Drug status is extremely helpful.
“The orphan drug designation provides significant benefits to pharmaceutical companies developing drugs for rare diseases, i.e. those impacting fewer than 200,000 people in the United Statesii. These benefits include market exclusivity, financial incentives, regulatory assistance, and support with drug development. Overall, the designation incentivizes and supports the development of certain treatments, increasing access to therapies for patients.”
The latest initiative is the development of NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain.
Here’s an exciting article delineating the USD68 billion potential of Orphan drugs and NRX’s potential in that scenario.
I need help understanding the pharmaceutical development process, but I can see the potential of NRX’s personnel, product mix, and business acumen. Not to mention the use of human trials to prove the tech.
You should, too.
Bob Beaty
For over 30 years, Bob Beaty has been explaining concepts and companies to the global investment community. One of the original writers for Jim Cramer’s Thestreet.com, he also wrote for AOL (Can/US), the Globe and Mail, and the Huffington Post. Over that period, he illuminated small-cap companies to investors with wit and pith but mostly opinion and facts. Investing should be fun. Pedantic, staid content is no fun.
Before embarking on his writing career, Bob had a successful international journey in the finance industry. He served as a broker, derivatives product manager, and a Director of London's Credit Suisse subsidiary. His career spanned across major financial hubs including Toronto, Vancouver, and the UK, giving him a unique global perspective. (He is still fondly remembering those English client lunches.)
Other than everything Groucho Marx and George Carlin ever said, Bob lives by a simple credo;
‘Never do anything the person standing in front of you can't understand.’ Hunter S. Thompson.
Let’s go.
